SEC Form 4 · accession 0001778623-26-000007
Dianthus Therapeutics, Inc. /DE/ · DNTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam M Veness
Officer — SVP, General Counsel and Sec.
Period of report
Aug 7, 2026
Accepted (ET)
Aug 11, 2026 · 5:08 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001690585
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 7, 2026 | M | 3,833 | $17.88 | A | 3,833 | D | |
| Common StockF2 | Aug 7, 2026 | S | 3,217 | $110.61 | D | 616 | D | |
| Common StockF3 | Aug 7, 2026 | S | 616 | $111.18 | D | 0 | D | |
| Common Stock | Aug 10, 2026 | M | 16,167 | $17.88 | A | 16,167 | D | |
| Common StockF4 | Aug 10, 2026 | S | 16,167 | $110.38 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $17.88 | Aug 7, 2026 | M | 3,833 | D | — | Jan 23, 2034 | Common Stock | 3,833 | 76,167 | D |
| Stock Option (Right to Buy)F5 | $17.88 | Aug 10, 2026 | M | 16,167 | D | — | Jan 23, 2034 | Common Stock | 16,167 | 60,000 | D |
Explanation of responses
- F1The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.07 to $111.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.08 to $111.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.00 to $110.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.